Bias analyses of preclinical and clinical D2 dopamine ligands: Studies with immediate and complex signaling pathways

Journal of Pharmacology and Experimental Therapeutics

Volumn 352, Issue 3, 2015, Pages 480-493

  Brust, Tarsis F ^a   Hayes, Michael P ^b   Roman, David L ^b   Burris, Kevin D ^c   Watts, Val J ^a  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; BETA ARRESTIN; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; MITOGEN ACTIVATED PROTEIN KINASE; DOPAMINE D2L RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LIGAND;

ANIMAL CELL; ARTICLE; CELL ASSAY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; MEDICAL RESEARCH; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; HAMSTER; PHYSIOLOGY; PRECLINICAL STUDY; RAT;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DOPAMINE AGENTS; DRUG EVALUATION, PRECLINICAL; LIGANDS; RATS; RECEPTORS, DOPAMINE D2; SIGNAL TRANSDUCTION;

EID: 84921525907     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.220293     Document Type: Article

References (46)

1. Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M, Peterson S, Yadav PN, Huang XP, Feng B, et al. (2011) Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci USA 108:18488-18493.
2. Beaulieu JM and Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63:182-217.
3. Black JW and Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162.
4. Bohn LM, Dykstra LA, Lefkowitz RJ, Caron MG, and Barak LS (2004) Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery. Mol Pharmacol 66:106-112.
5. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, and Caron MG (2000) Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408:720-723.
6. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, and Lin FT (1999) Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286: 2495-2498.
7. Brust TF, Hayes MP, Roman DL, and Watts VJ (2015) New functional activity of aripiprazole revealed: robust antagonism of D2 dopamine receptor-stimulated Gβγ signaling. Biochem Pharmacol 93:85-91.
8. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, and Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389.
9. Conley JM, Brust TF, Xu R, Burris KD, and Watts VJ (2014) Drug-induced sensitization of adenylyl cyclase: assay streamlining and miniaturization for small molecule and siRNA screening applications. J Vis Exp 83:e51218.
10. Cooper DM and Crossthwaite AJ (2006) Higher-order organization and regulation of adenylyl cyclases. Trends Pharmacol Sci 27:426-431.
11. Deshpande DA, Theriot BS, Penn RB, and Walker JK (2008) Beta-arrestins specifically constrain beta2-adrenergic receptor signaling and function in airway smooth muscle. FASEB J 22:2134-2141.
12. DeWire SM and Violin JD (2011) Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. Circ Res 109:205-216.
13. Ehlert FJ (2008) On the analysis of ligand-directed signaling at G protein-coupled receptors. Naunyn Schmiedebergs Arch Pharmacol 377:549-577.
14. Ejendal KF, Dessauer CW, Hébert TE, and Watts VJ (2012) Dopamine D(2) receptor-mediated heterologous sensitization of AC5 requires signalosome assembly. J Signal Transduct 2012:210324.
15. Fang Y, Ferrie AM, Fontaine NH, Mauro J, and Balakrishnan J (2006) Resonant waveguide grating biosensor for living cell sensing. Biophys J 91:1925-1940.
16. Federman AD, Conklin BR, Schrader KA, Reed RR, and Bourne HR (1992) Hormonal stimulation of adenylyl cyclase through Gi-protein beta gamma subunits. Nature 356:159-161.
17. 2-adrenergic receptors. Sci Rep 4:3828.
18. Gay EA, Urban JD, Nichols DE, Oxford GS, and Mailman RB (2004) Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. Mol Pharmacol 66:97-105.
19. Griffin MT, Figueroa KW, Liller S, and Ehlert FJ (2007) Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o,Gs, and G15. J Pharmacol Exp Ther 321:1193-1207.
20. Kenakin T (2014) What is pharmacological 'affinity'? Relevance to biased agonism and antagonism. Trends Pharmacol Sci 35 :434-441.
21. Kenakin T and Christopoulos A (2013a) Measurements of ligand bias and functional affinity. Nat Rev Drug Discov 12:483.
22. Kenakin T and Christopoulos A (2013b) Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12: 205-216.
23. Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, and Novick S (2012) A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci 3:193-203.
24. Kent RS, De Lean A, and Lefkowitz RJ (1980) A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data. Mol Pharmacol 17:14-23.
25. Klewe IV, Nielsen SM, Tarpo L, Urizar E, Dipace C, Javitch JA, Gether U, Egebjerg J, and Christensen KV (2008) Recruitment of beta-arrestin2 to the dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling. Neuropharmacology 54:1215-1222.
26. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, and Mailman RB (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627.
27. Lefkowitz RJ and Shenoy SK (2005) Transduction of receptor signals by betaarrestins. Science 308:512-517.
28. Lin Y and Smrcka AV (2011) Understanding molecular recognition by G protein βγ subunits on the path to pharmacological targeting. Mol Pharmacol 80:551-557.
29. Masri B, Salahpour A, Didriksen M, Ghisi V, Beaulieu JM, Gainetdinov RR, and Caron MG (2008) Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci USA 105:13656-13661.
30. Nygaard R, Zou Y, Dror RO, Mildorf TJ, Arlow DH, Manglik A, Pan AC, Liu CW, Fung JJ, Bokoch MP, et al. (2013) The dynamic process of β(2)-adrenergic receptor activation. Cell 152:532-542.
31. Oak JN, Lavine N, and Van Tol HHM (2001) Dopamine D-4 and D-2L receptor stimulation of the mitogen-activated protein kinase pathway is dependent on transactivation of the platelet-derived growth factor receptor. Mol Pharmacol 60:92-103.
32. Quan W, Kim JH, Albert PR, Choi H, and Kim KM (2008) Roles of G protein and beta-arrestin in dopamine D2 receptor-mediated ERK activation. Biochem Biophys Res Commun 377:705-709.
33. Rajagopal S (2013) Quantifying biased agonism: understanding the links between affinity and efficacy. Nat Rev Drug Discov 12:483.
34. Rajagopal S, Ahn S, Rominger DH, Gowen-MacDonald W, Lam CM, Dewire SM, Violin JD, and Lefkowitz RJ (2011) Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol 80 :367-377.
35. Schröder R, Schmidt J, Blättermann S, Peters L, Janssen N, Grundmann M, Seemann W, Kaufel D, Merten N, Drewke C, et al. (2011) Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. Nat Protoc 6:1748-1760.
36. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, and Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411.
37. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13.
38. Vidi PA, Chemel BR, Hu CD, and Watts VJ (2008) Ligand-dependent oligomerization of dopamine D(2) and adenosine A(2A) receptors in living neuronal cells. Mol Pharmacol 74:544-551.
39. Wang WC, Mihlbachler KA, Brunnett AC, and Liggett SB (2009) Targeted transgenesis reveals discrete attenuator functions of GRK and PKA in airway beta2-adrenergic receptor physiologic signaling. Proc Natl Acad Sci USA 106: 15007-15012.
40. Watts VJ (2002) Molecular mechanisms for heterologous sensitization of adenylate cyclase. J Pharmacol Exp Ther 302:1-7.
41. Watts VJ and Neve KA (2005) Sensitization of adenylate cyclase by Gα i/o-coupled receptors. Pharmacol Ther 106:405-421.
42. Watts VJ and Neve KA (1996) Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors. Mol Pharmacol 50:966-976.
43. Watts VJ and Neve KA (1997) Activation of type II adenylate cyclase by D2 and D4 but not D3 dopamine receptors. Mol Pharmacol 52:181-186.
44. Whalen EJ, Rajagopal S, and Lefkowitz RJ (2011) Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med 17:126-139.
45. Zhao X, Jones A, Olson KR, Peng K, Wehrman T, Park A, Mallari R, Nebalasca D, Young SW, and Xiao SH (2008) A homogeneous enzyme fragment complementation-based beta-arrestin translocation assay for high-throughput screening of G-proteincoupled receptors. J Biomol Screen 13:737-747.
46. Zhu W, Tilley DG, Myers VD, Coleman RC, and Feldman AM (2013) Arginine vasopressin enhances cell survival via a G protein-coupled receptor kinase 2/β-arrestin1/extracellular-regulated kinase 1/2-dependent pathway in H9c2 cells. Mol Pharmacol 84:227-235.